Clinical potential of undercarboxylated osteocalcin in metabolic and neurodegenerative diseases: From biomarker to therapeutic target
Peer-Reviewed Publication
Updates every hour. Last Updated: 2-Jan-2026 22:11 ET (3-Jan-2026 03:11 GMT/UTC)
Osteocalcin (OCN), a non-collagenous protein synthesized by osteoblasts, is integral to bone mineralization and demonstrates significant effects on metabolic and neurological functions. Its undercarboxylated form, Glu-OCN, has emerged as a key regulator of glucose metabolism in diabetes, bone density in osteoporosis (OP), and lipid metabolism in conditions such as nonalcoholic fatty liver disease (NAFLD). Additionally, Glu-OCN is implicated in neurodegenerative and cardiovascular diseases through its roles in neurotransmitter synthesis and vascular calcification, respectively. This review examines the essential functions of Glu-OCN in the management of metabolic and neurodegenerative disorders, emphasizing its significance as both a diagnostic biomarker and therapeutic target. While findings to date are promising, most studies remain observational. Advanced detection methodologies and extensive longitudinal studies are urgently needed to elucidate the mechanisms and clinical applications of Glu-OCN. Advancements in this area could facilitate the integration of Glu-OCN into personalized medicine approaches, improving early diagnosis, risk assessment, and treatment monitoring.
Researchers at the National Institutes of Health (NIH) have shown for the first time that a type of human papillomavirus (HPV) commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma (cSCC) when certain immune cells malfunction. cSCC is one of the most common cancers in the United States and worldwide. Previously, scientists believed HPV merely facilitated the accumulation of DNA mutations caused by ultraviolet (UV) radiation, usually the primary driver of cSCC. The findings were published today in The New England Journal of Medicine.
In low-resource settings, babies born with gastroschisis — a congenital condition in which the developing intestines extend outside the body through a hole in the abdominal wall —face life-threatening challenges. While survival rates in high-income countries now exceed 90% thanks to advanced medical tools and neonatal care, infants in resource-constrained medical settings still face high mortality rates, partially because of a lack of access to the lifesaving equipment needed to treat the condition. A team of engineers and pediatric surgeons led by Rice University’s Rice360 Institute for Global Health Technologies is working to change that. Their innovation? A simple, low-cost and locally manufacturable medical device, known as the “SimpleSilo,” designed to provide lifesaving treatment for gastroschisis at a fraction of the current cost and made from locally available materials.